Inotersen (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inotersen" in English language version.

refsWebsite

Global rank English rank

7web.archive.org

1^st place

4nih.gov

4^th place

3fda.gov

447^th place

338^th place

2doi.org

2^nd place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1semanticscholar.org

11^th place

8^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Benson MD, Dasgupta NR, Monia BP (February 2019). "Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis". Neurodegenerative Disease Management. 9 (1): 25–30. doi:10.2217/nmt-2018-0037. PMID 30561247. S2CID 56178847.
Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, et al. (June 2020). "Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis". Nucleic Acid Therapeutics. 30 (3): 153–163. doi:10.1089/nat.2019.0822. PMC 7249474. PMID 32286934.{{cite journal}}: CS1 maint: overridden setting (link)

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Tegsedi EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 October 2020. Retrieved 3 October 2020.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"Drug Trial Snapshot: Tegsedi". U.S. Food and Drug Administration (FDA). 23 July 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2018. U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original (PDF) on 17 September 2020. Retrieved 16 September 2020.

accessdata.fda.gov

"Inotersen Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 July 2012. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.

hres.ca (Global: low place; English: low place)

pdf.hres.ca

"Tegsedi inotersen injection" (PDF). Product Monograph Including Patient Medication Information. Akcea Therapeutics, Inc. Archived (PDF) from the original on 1 June 2022. Retrieved 1 June 2022 – via The Drug and Health Product Register, Government of Canada.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Tegsedi 284 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 15 October 2019. Archived from the original on 7 October 2020. Retrieved 3 October 2020.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Benson MD, Dasgupta NR, Monia BP (February 2019). "Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis". Neurodegenerative Disease Management. 9 (1): 25–30. doi:10.2217/nmt-2018-0037. PMID 30561247. S2CID 56178847.
Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, et al. (June 2020). "Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis". Nucleic Acid Therapeutics. 30 (3): 153–163. doi:10.1089/nat.2019.0822. PMC 7249474. PMID 32286934.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Tegsedi- inotersen injection, solution". DailyMed. 2 September 2020. Archived from the original on 7 October 2020. Retrieved 3 October 2020.

ncbi.nlm.nih.gov

Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, et al. (June 2020). "Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis". Nucleic Acid Therapeutics. 30 (3): 153–163. doi:10.1089/nat.2019.0822. PMC 7249474. PMID 32286934.{{cite journal}}: CS1 maint: overridden setting (link)

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Benson MD, Dasgupta NR, Monia BP (February 2019). "Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis". Neurodegenerative Disease Management. 9 (1): 25–30. doi:10.2217/nmt-2018-0037. PMID 30561247. S2CID 56178847.

web.archive.org (Global: 1^st place; English: 1^st place)

"Tegsedi inotersen injection" (PDF). Product Monograph Including Patient Medication Information. Akcea Therapeutics, Inc. Archived (PDF) from the original on 1 June 2022. Retrieved 1 June 2022 – via The Drug and Health Product Register, Government of Canada.
"Tegsedi 284 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 15 October 2019. Archived from the original on 7 October 2020. Retrieved 3 October 2020.
"Tegsedi- inotersen injection, solution". DailyMed. 2 September 2020. Archived from the original on 7 October 2020. Retrieved 3 October 2020.
"Tegsedi EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 October 2020. Retrieved 3 October 2020.
"Drug Trial Snapshot: Tegsedi". U.S. Food and Drug Administration (FDA). 23 July 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2018. U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original (PDF) on 17 September 2020. Retrieved 16 September 2020.
"Inotersen Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 July 2012. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.